<DOC>
	<DOCNO>NCT00959868</DOCNO>
	<brief_summary>This single centre , open label , phase I dose escalation trial use modify accelerated titration design . Patients superficial bladder tumour ( Ta T1 ) CIS candidate transurethral resection muscle invasive disease ( &gt; T2 ) candidate radical cystectomy enrol . OGX-427 give neoadjuvantly 8 day , follow transurethral resection ( superficial disease ) radical cystectomy ( muscle invasive disease ) . Baseline Hsp27 level determine pre-treatment cytological sample bladder washing tumour biopsy perform prior therapy . Post-treatment PK PD data determine TUR ( Ta , T1 tumour ) radical cystectomy ( T2 tumour ) specimen . A recommended phase II dose determine toxicity , tissue pK , percentage Hsp27 knockdown . Effects treatment Hsp27 client protein level apoptotic index also evaluate . Evaluation protocol treatment take place assess toxicity . Assessments occur various visit per Evaluation Schedule . Adverse event evaluation base NCI CTCAEv3.0 . For quality life assessment treatment , EORTC QLC-BLS24 use first treatment ( day 1 ) prior surgery ( TURBT radical cystectomy ) . The Day 1 QOL assessment serve baseline . After removal protocol treatment , subject follow toxicity relate study drug 30 day . After study , subject follow accord standard care . Follow-up tumour recurrence superficial tumour assess every three month cystoscopic examination two year , every six month next two year , yearly thereafter .</brief_summary>
	<brief_title>A Study Treatment Superficial Bladder Cancer Using OGX-427</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>1 . Patient age must &gt; 18 2 . Histologic evidence bladder cancer ( superficial muscle invasive ) CIS evidence : Patients present superficial tumour unknown pathological stage inclinic bladder washing ( perform cystoscopically ) biopsy ( cup biopsy ) . Patients recurrent superficial disease ( Ta T1 ) tissue available baseline study ( i.e . tissue previous transurethral resection store paraffin block ) eligible trial without require cytology biopsy . Patients previously diagnose T1 tumour require reresection bladder tumour eligible tissue original TURBT available baseline study . Patients present muscle invasive ( &gt; T2 ) disease eligible candidate radical cystectomy baseline tissue initial resection available baseline study 3 . No intravesical therapy within previous 6 month 4 . No evidence metastatic disease determine physical exam , CT scan chest xray , indicate . 5 . ECOG status must 0 , 1 , 2 6 . Laboratory requirement ( within 7 day treatment ) : negative urine culture Absolute neutrophils count &gt; 1.5 x 109 cells/L , platelet count &gt; 100 x 109/L , Total bilirubin &lt; 1.5 x upper normal limit ( ULN ) , AST and/or ALT &lt; 1.5 x ULN , alkaline phosphatase &lt; 1.5 x ULN , serum creatinine &lt; 1.5 x ULN . PTT INR , within normal limit 7 . Patient must able complete quality life questionnaires either English French 8 . Patients must provide write informed consent . 1 . Patients `` indeterminate '' `` negative '' result biopsy cytology ineligible trial . 2 . Patients take warfarin Coumadin anticoagulation therapy bleed disorder . NOTE : Patients require anticoagulation therapy study remove study treatment . 3 . Pregnant lactate woman 4 . Patients accessible followup 5 . Patients active urinary tract infection , upper tract urothelial tumor , active infection include tuberculosis , concurrent febrile illness impair immune response cause 6 . Patients contraindication spinal general anesthesia require transurethral resection radical cystectomy 7 . Recent ( &lt; 14 day ) urethral trauma inability perform catheterization cystoscopy safely 8 . Patients know serious illness medical condition would impair protocol treatment delivery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Bladder cancer</keyword>
	<keyword>Superficial bladder cancer ( Ta T1 )</keyword>
	<keyword>Muscle invasive bladder cancer ( T2 )</keyword>
	<keyword>Transurethral resection</keyword>
	<keyword>Radical cystectomy</keyword>
	<keyword>OGX-427</keyword>
	<keyword>Antisense oligonucleotide</keyword>
	<keyword>Heat shock protein 27</keyword>
	<keyword>superficial bladder tumour ( Ta T1 ) CIS prior transurethral resection</keyword>
	<keyword>Muscle invasive ( T2 ) bladder cancer prior radical cystectomy</keyword>
</DOC>